Pills would be more convenient for patients and also easier to manufacture at large scale than other top weight-loss drugs, which require , CEO Dave Ricks said.

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

Eli Lilly has asked the U.S. government to pause the new law that allows Medicare to negotiate prices for its costliest ...

Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which ...

And GSK said it would pay up to $1.15 billion privately-held IDRx, a clinical-stage biopharmaceutical company developing therapeutics for the treatment of GIST, which stands for Gastrointestinal ...

The Indianapolis-based drugmaker will acquire Scorpion’s STX-478, a once-daily oral treatment in early trials for breast cancer and other advanced solid tumors.

Eli Lilly and Company (LLY) on Monday said it has agreed to buy Scorpion Therapeutics' experimental cancer therapy PI3Ka inhibitor ...

As drugs emerge as vital to the Government’s anti-obesity strategy, BBC Panorama sheds light on the pharmaceuticals industry behind them ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Eli Lilly said on Monday it plans to buy Scorpion Therapeutics' experimental cancer therapy for up to $2.5 billion in cash to ...

The pharma will spend up to $2.5 billion to acquire an experimental PI3K inhibitor from Scorpion, which will spin out a new ...

The biopharma industry’s deal-a-palooza, better known as the J.P. Morgan Healthcare Conference, has kicked off in San ...